Non-surgical Management After NIT for dMMR/MSI-H GC

Non-surgical Management After Neoadjuvant Immunotherapy for Locally Advanced dMMR/MSI-H Gastric Cancer: WWWGC Phase II Study

Status

Enrolling by invitation

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07646574

Enrollment

Registered

2026-06-12

Start date

2026-07-01

Completion date

2027-06-30

Last updated

2026-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-surgical Management;dMMR/MSI-H Gastric Cancer;Neoadjuvant Immunotherapy

Brief summary

Gastric cancer is one of the most common cancers worldwide and has a poor prognosis Immunotherapy significantly improves the prognosis of gastric cancer. In resectable gastric/gastroesophageal junction adenocarcinoma (GAC/GEJA) C, mismatch repair deficiency (dMMR)/microsatellite instability (MSI-H) can improve survival, and immunotherapy can avoid chemotherapy or surgery. The dMMR/MSI-H status is the strongest predictive biomarker for the benefit of immunotherapy with anti-programmed death receptor 1 and its ligands (PD-1/PD-L1) in advanced solid tumors, especially metastatic gastric/gastroesophageal junction adenocarcinoma. The INFINITY study provides Durvalumab combined with Tremelimumab as a treatment option with significant benefits for preoperative treatment of dMMR/MSI GAC/GEJAC, as well as the feasibility of non-surgical treatment strategies for such gastric cancer patients At present, there are no studies related to Asian gastric cancer patients, which are worthy of further verification and exploration in Asian gastric cancer cohorts.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

Patients over 18 years old with advanced dMMR/MSI-H gastric cancer; Neoadjuvant therapy is needed (immunotherapy, chemotherapy + immunotherapy); The patient voluntarily and agreed to join the clinical research.

Exclusion criteria

Gastric cancer combined with invasion and metastasis; Gastric cancer combined with other malignant tumors; Gastric cancer combined with dysfunction of other organs; Unwilling to participate in clinical research.

Design outcomes

Primary

Measure	Time frame	Description
Recurrence-free survival (RFS)	One year, three years, or five years after the end of immunotherapy	The recurrence-free survival time of gastric cancer patients
Overall survival (OS)	One year, three years, or five years after the end of immunotherapy	The period from the start of randomization grouping in a clinical trial to the death of a patient for any cause

Countries

China

Contacts

STUDY_DIRECTORyong zhou, Professor

West China Hospital

Outcome results